Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Fierce Pharma
Merck grows more ambitious about 'workhorse' TROP2 ADC
Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liu
Oct 20, 2025 4:00pm
ESMO: Roche wants oral SERD to benefit 'all comers'
Oct 18, 2025 1:00am
ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals
Oct 17, 2025 10:30am
Spanish oncology group infuses AI into breast cancer trials
Oct 7, 2025 6:05am
IceCure nabs FDA OK for breast cancer cryoablation treatment
Oct 6, 2025 9:00am
Foundation Medicine awards new grant for biommarker testing push
Oct 6, 2025 8:45am
